Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies

Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies

Introduction: Janus kinase inhibitors (JAK-i), a class of targeted synthetic disease-modifying antirheumatic drugs (tDMARDs), are suggested as second or third-line therapies in rheumatoid arthritis (RA). Synthesized cost-effective evidence would aid in informed decision-making given the similar clin...

Full description

Bibliographic Details
Main Authors: S. Sajith Kumar, Madhumitha Haridoss, Krishnamurthy Venkataraman, Bhavani Shankara Bagepally
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Pharmacology
Subjects:
rheumatoid arthritis
janus kinase inhibitors
cost-effectiveness
QALY
evidence syntheses
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1090361/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1090361/full

Similar Items